drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3 values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00313 | DB01619 | 556 | 830 | [
"DDInter1913",
"DDInter1441"
] | Valproic acid | Phenindamine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects of khelline when he found that all of his samples, dissolved in valproic acid, exerted a similar degree of anticonvulsive activity. It first received approval on February 28, 1978 from the FDA under the trade name Depakene. Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects. It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures. | Moderate | 1 | [
[
[
556,
24,
830
]
],
[
[
556,
24,
537
],
[
537,
40,
830
]
],
[
[
556,
24,
13
],
[
13,
24,
830
]
],
[
[
556,
24,
104
],
[
104,
1,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Phenindamine (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Mirtazapine (Compound) and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Mirtazapine (Compound) and Mirtazapine (Compound) resembles Phenindamine (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound) |
DB00054 | DB00939 | 1,432 | 1,338 | [
"DDInter6",
"DDInter1135"
] | Abciximab | Meclofenamic acid | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
1432,
24,
1338
]
],
[
[
1432,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
1432,
25,
1347
],
[
1347,
24,
1338
]
],
[
[
1432,
64,
1271
],
[
12... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Abciximab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Abciximab may lead to a major life threatening interaction when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Abciximab may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Abciximab may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Meclofenamic acid
Abciximab may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Meclofenamic acid
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Meclofenamic acid (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid |
DB00480 | DB08904 | 1,668 | 375 | [
"DDInter1035",
"DDInter342"
] | Lenalidomide | Certolizumab pegol | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019. | Major | 2 | [
[
[
1668,
25,
375
]
],
[
[
1668,
24,
200
],
[
200,
63,
375
]
],
[
[
1668,
63,
66
],
[
66,
24,
375
]
],
[
[
1668,
25,
671
],
[
671,
2... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Lenalidomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Lenalidomide may lead to a major life threatening interaction when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Lenalidomide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Lenalidomide may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Certolizumab pegol
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may lead to a major life threatening interaction when taken with Certolizumab pegol
Lenalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine and Rotavirus vaccine may lead to a major life threatening interaction when taken with Certolizumab pegol |
DB00208 | DB09104 | 1,018 | 286 | [
"DDInter1804",
"DDInter1118"
] | Ticlopidine | Magnesium hydroxide | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine. | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used commercially as a fire retardant. It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). | Minor | 0 | [
[
[
1018,
23,
286
]
],
[
[
1018,
24,
109
],
[
109,
23,
286
]
],
[
[
1018,
23,
1252
],
[
1252,
23,
286
]
],
[
[
1018,
25,
1468
],
[
1468,
... | [
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ticlopidine may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ticlopidine may lead to a major life threatening interaction when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ticlopidine may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide |
DB00762 | DB06717 | 613 | 875 | [
"DDInter973",
"DDInter778"
] | Irinotecan | Fosaprepitant | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde). | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
613,
24,
875
]
],
[
[
613,
63,
723
],
[
723,
1,
875
]
],
[
[
613,
21,
29180
],
[
29180,
60,
875
]
],
[
[
613,
24,
466
],
[
466,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Irinotecan (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fosaprepitant
Irinotecan may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant
Irinotecan may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant |
DB00196 | DB09237 | 600 | 1,586 | [
"DDInter743",
"DDInter1045"
] | Fluconazole | Levamlodipine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019. | Moderate | 1 | [
[
[
600,
24,
1586
]
],
[
[
600,
23,
466
],
[
466,
62,
1586
]
],
[
[
600,
24,
578
],
[
578,
23,
1586
]
],
[
[
600,
24,
870
],
[
870,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Fluconazole may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Fluconazole may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Levamlodipine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Levamlodipine |
DB00382 | DB01097 | 62 | 1,377 | [
"DDInter1734",
"DDInter1033"
] | Tacrine | Leflunomide | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
62,
25,
1377
]
],
[
[
62,
24,
112
],
[
112,
24,
1377
]
],
[
[
62,
24,
1491
],
[
1491,
64,
1377
]
],
[
[
62,
23,
1001
],
[
1001,
... | [
[
[
"Tacrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may lead to a major life threatening interaction when taken with Leflunomide
Tacrine may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine and Mechlorethamine may lead to a major life threatening interaction when taken with Leflunomide
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may lead to a major life threatening interaction when taken with Leflunomide
Tacrine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Leflunomide
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may lead to a major life threatening interaction when taken with Leflunomide
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Tacrine may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine and Mechlorethamine (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Leflunomide (Compound) |
DB01067 | DB01261 | 959 | 170 | [
"DDInter826",
"DDInter1679"
] | Glipizide | Sitagliptin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006. | Moderate | 1 | [
[
[
959,
24,
170
]
],
[
[
959,
5,
11640
],
[
11640,
44,
170
]
],
[
[
959,
6,
8374
],
[
8374,
45,
170
]
],
[
[
959,
21,
28921
],
[
28921,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Glipizide",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"... | Glipizide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Glipizide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sitagliptin (Compound)
Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Glipizide may lead to a major life threatening interaction when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin |
DB00704 | DB01230 | 267 | 795 | [
"DDInter1263",
"DDInter1416"
] | Naltrexone | Pemoline | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | Moderate | 1 | [
[
[
267,
24,
795
]
],
[
[
267,
24,
1613
],
[
1613,
63,
795
]
],
[
[
267,
63,
305
],
[
305,
24,
795
]
],
[
[
267,
25,
1510
],
[
1510,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pemoline"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Naltrexone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Pemoline
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Pemoline
Naltrexone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Pemoline
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Naltrexone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pemoline |
DB00635 | DB06688 | 1,573 | 1,430 | [
"DDInter1515",
"DDInter1677"
] | Prednisone | Sipuleucel-T | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. | Moderate | 1 | [
[
[
1573,
24,
1430
]
],
[
[
1573,
1,
175
],
[
175,
24,
1430
]
],
[
[
1573,
25,
676
],
[
676,
63,
1430
]
],
[
[
1573,
24,
1531
],
[
1531,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a... | Prednisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sipuleucel-T |
DB00370 | DB12332 | 1,251 | 1,619 | [
"DDInter1230",
"DDInter1626"
] | Mirtazapine | Rucaparib | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1251,
24,
1619
]
],
[
[
1251,
25,
222
],
[
222,
23,
1619
]
],
[
[
1251,
23,
112
],
[
112,
23,
1619
]
],
[
[
1251,
24,
1662
],
[
1662,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutram... | Mirtazapine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Mirtazapine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Mirtazapine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Rucaparib
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Rucaparib
Mirtazapine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Rucaparib |
DB01097 | DB13873 | 1,377 | 1,534 | [
"DDInter1033",
"DDInter719"
] | Leflunomide | Fenofibric acid | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed for improved solubility, gastrointestinal absorption, and bioavailability, and more convenient administration.[A32038,A193362] | Major | 2 | [
[
[
1377,
25,
1534
]
],
[
[
1377,
64,
267
],
[
267,
24,
1534
]
],
[
[
1377,
25,
1613
],
[
1613,
24,
1534
]
],
[
[
1377,
63,
959
],
[
959,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
... | Leflunomide may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Fenofibric acid
Leflunomide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Fenofibric acid
Leflunomide may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may lead to a major life threatening interaction when taken with Fenofibric acid
Leflunomide may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Leflunomide may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid |
DB00722 | DB00959 | 743 | 1,486 | [
"DDInter1079",
"DDInter1191"
] | Lisinopril | Methylprednisolone | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Moderate | 1 | [
[
[
743,
24,
1486
]
],
[
[
743,
63,
175
],
[
175,
40,
1486
]
],
[
[
743,
24,
167
],
[
167,
1,
1486
]
],
[
[
743,
24,
617
],
[
617,
4... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Methylprednisolone (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Methylprednisolone (Compound)
Lisinopril (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Methylprednisolone (Compound)
Lisinopril (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Methylprednisolone (Compound)
Lisinopril may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone |
DB00530 | DB08938 | 1,195 | 1,384 | [
"DDInter667",
"DDInter1112"
] | Erlotinib | Magaldrate | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1195,
24,
1384
]
],
[
[
1195,
24,
1220
],
[
1220,
23,
1384
]
],
[
[
1195,
63,
752
],
[
752,
23,
1384
]
],
[
[
1195,
63,
362
],
[
362,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may lead to a major life threatening interaction when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Valproic acid and Valproic acid may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate |
DB00448 | DB00673 | 1,215 | 723 | [
"DDInter1022",
"DDInter112"
] | Lansoprazole | Aprepitant | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Moderate | 1 | [
[
[
1215,
24,
723
]
],
[
[
1215,
24,
875
],
[
875,
40,
723
]
],
[
[
1215,
6,
7950
],
[
7950,
45,
723
]
],
[
[
1215,
21,
28890
],
[
28890,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Lansoprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Lansoprazole (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Aprepitant (Compound)
Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Lansoprazole may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Lansoprazole may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant |
DB06317 | DB11793 | 1,626 | 738 | [
"DDInter630",
"DDInter1297"
] | Elotuzumab | Niraparib | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019. | Moderate | 1 | [
[
[
1626,
24,
738
]
],
[
[
1626,
63,
663
],
[
663,
24,
738
]
],
[
[
1626,
24,
496
],
[
496,
24,
738
]
],
[
[
1626,
24,
1129
],
[
1129,
... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Elotuzumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Niraparib
Elotuzumab may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Niraparib
Elotuzumab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Niraparib
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib |
DB00446 | DB11989 | 597 | 1,434 | [
"DDInter351",
"DDInter183"
] | Chloramphenicol | Benznidazole | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
597,
24,
1434
]
],
[
[
597,
24,
788
],
[
788,
24,
1434
]
],
[
[
597,
24,
148
],
[
148,
63,
1434
]
],
[
[
597,
63,
289
],
[
289,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin (Compound) and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole |
DB01110 | DB06077 | 86 | 879 | [
"DDInter1209",
"DDInter1102"
] | Miconazole | Lumateperone | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-based products are available.[L14021, L14024, L14027, L14033, L14396] Miconazole is thought to act primarily through the inhibition of fungal CYP450 14α-lanosterol demethylase activity.[A203636, A203639] Miconazole was first synthesized in 1969 and first granted FDA approval on January 8, 1974, for sale by INSIGHT Pharmaceuticals as a topical cream.[A214523, L14021] It is currently available as a variety of prescription and over the counter products. Despite having been in clinical use for an extended period, resistance to m | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.[A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.[A189093,L10908] | Moderate | 1 | [
[
[
86,
24,
879
]
],
[
[
86,
24,
214
],
[
214,
63,
879
]
],
[
[
86,
24,
392
],
[
392,
24,
879
]
],
[
[
86,
63,
1144
],
[
1144,
24,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Miconazole may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Miconazole may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Miconazole may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Lumateperone
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Lumateperone
Miconazole may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Lumateperone |
DB00078 | DB11003 | 1,172 | 748 | [
"DDInter898",
"DDInter100"
] | Ibritumomab tiuxetan | Anthrax vaccine | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world. | Moderate | 1 | [
[
[
1172,
24,
748
]
],
[
[
1172,
25,
676
],
[
676,
63,
748
]
],
[
[
1172,
24,
1683
],
[
1683,
24,
748
]
],
[
[
1172,
64,
1057
],
[
1057,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine |
DB00390 | DB12010 | 1,252 | 214 | [
"DDInter554",
"DDInter785"
] | Digoxin | Fostamatinib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Moderate | 1 | [
[
[
1252,
24,
214
]
],
[
[
1252,
24,
976
],
[
976,
24,
214
]
],
[
[
1252,
25,
1166
],
[
1166,
24,
214
]
],
[
[
1252,
24,
1017
],
[
1017,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Digoxin may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Digoxin may cause a minor interaction that can limit clinical effects when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Digoxin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Fostamatinib
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Fostamatinib
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib |
DB01592 | DB09472 | 1,596 | 1,383 | [
"DDInter975",
"DDInter1693"
] | Iron | Sodium sulfate | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletion of iron stores may result in iron-deficiency anemia. Iron is used to build up the blood in anemia. | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions. | Moderate | 1 | [
[
[
1596,
24,
1383
]
],
[
[
1596,
63,
839
],
[
839,
25,
1383
]
],
[
[
1596,
63,
839
],
[
839,
25,
609
],
[
609,
24,
1383
]
],
[
[
1596,
... | [
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"... | Iron may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Sodium sulfate
Iron may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Iron (Compound) causes Wheezing (Side Effect) and Wheezing (Side Effect) is caused by Morphine (Compound) and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Iron may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Iron (Compound) causes Nasal congestion (Side Effect) and Nasal congestion (Side Effect) is caused by Thioridazine (Compound) and Thioridazine may lead to a major life threatening interaction when taken with Sodium sulfate
Iron may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Iron may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Iron may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Iron (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate |
DB00054 | DB01166 | 1,432 | 477 | [
"DDInter6",
"DDInter379"
] | Abciximab | Cilostazol | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
1432,
24,
477
]
],
[
[
1432,
23,
297
],
[
297,
62,
477
]
],
[
[
1432,
25,
126
],
[
126,
23,
477
]
],
[
[
1432,
24,
109
],
[
109,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clov... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Abciximab may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Abciximab may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Abciximab may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Abciximab may lead to a major life threatening interaction when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Abciximab may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Cilostazol |
DB00242 | DB15233 | 1,064 | 1,650 | [
"DDInter392",
"DDInter142"
] | Cladribine | Avapritinib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a similar mechanism with [ripretinib]. Avapritinib was granted FDA approval on 9 January 2020 and EMA approval on 24 September 2020. | Major | 2 | [
[
[
1064,
25,
1650
]
],
[
[
1064,
25,
1101
],
[
1101,
24,
1650
]
],
[
[
1064,
64,
1257
],
[
1257,
24,
1650
]
],
[
[
1064,
24,
869
],
[
869... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} ... | Cladribine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cladribine may lead to a major life threatening interaction when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cladribine may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Avapritinib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Avapritinib
Cladribine may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Avapritinib
Cladribine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cladribine may lead to a major life threatening interaction when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cladribine may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib |
DB08895 | DB15965 | 976 | 1,330 | [
"DDInter1825",
"DDInter1270"
] | Tofacitinib | Naxitamab | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors), and is rarely subject to antigen loss. The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of naxitamab therapy markedly simpler than that of its predecessor. | Major | 2 | [
[
[
976,
25,
1330
]
],
[
[
976,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
976,
64,
1532
],
[
1532,
24,
1330
]
],
[
[
976,
25,
1480
],
[
1480,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Tofacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Tofacitinib may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tofacitinib may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tofacitinib may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Naxitamab
Tofacitinib may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Naxitamab
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Tofacitinib may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab |
DB00305 | DB05273 | 377 | 507 | [
"DDInter1232",
"DDInter1638"
] | Mitomycin | Samarium (153Sm) lexidronam | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries. | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. | Major | 2 | [
[
[
377,
25,
507
]
],
[
[
377,
24,
248
],
[
248,
24,
507
]
],
[
[
377,
24,
270
],
[
270,
63,
507
]
],
[
[
377,
25,
970
],
[
970,
25,... | [
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Mitomycin may lead to a major life threatening interaction when taken with Fluorouracil and Fluorouracil may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Mitomycin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab and Naxitamab may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Mitomycin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam |
DB00502 | DB11186 | 1,300 | 1,609 | [
"DDInter853",
"DDInter1427"
] | Haloperidol | Pentoxyverine | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states. It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed. | Moderate | 1 | [
[
[
1300,
24,
1609
]
],
[
[
1300,
24,
104
],
[
104,
24,
1609
]
],
[
[
1300,
63,
999
],
[
999,
24,
1609
]
],
[
[
1300,
40,
78
],
[
78,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol (Compound) resembles Droperidol (Compound) and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol (Compound) resembles Droperidol (Compound) and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine |
DB00188 | DB14443 | 168 | 987 | [
"DDInter222",
"DDInter1931"
] | Bortezomib | Vibrio cholerae CVD 103-HgR strain live antigen | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks. Cholera outbreaks remain a major global public health problem that mainly affects countries with limited access to clean water, poor hygiene, and proper sanitation; thus, effective vaccines to protect individuals against cholera disease are critical. The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera prevention to become available in the U.S. Vaxchora was later approved by the European Commission in April 2020. It is indicated for individuals aged two years and older. | Moderate | 1 | [
[
[
168,
24,
987
]
],
[
[
168,
24,
1480
],
[
1480,
24,
987
]
],
[
[
168,
23,
1220
],
[
1220,
24,
987
]
],
[
[
168,
63,
305
],
[
305,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen |
DB00653 | DB01285 | 544 | 708 | [
"DDInter1120",
"DDInter445"
] | Magnesium sulfate | Corticotropin | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083) | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
544,
24,
708
]
],
[
[
544,
24,
1436
],
[
1436,
63,
708
]
],
[
[
544,
63,
355
],
[
355,
24,
708
]
],
[
[
544,
24,
336
],
[
336,
2... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may lead to a major life threatening interaction when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Licorice and Licorice may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin |
DB05015 | DB14730 | 1,077 | 1,412 | [
"DDInter174",
"DDInter264"
] | Belinostat | Calaspargase pegol | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
1077,
24,
1412
]
],
[
[
1077,
24,
850
],
[
850,
24,
1412
]
],
[
[
1077,
63,
482
],
[
482,
24,
1412
]
],
[
[
1077,
64,
581
],
[
581,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Belinostat may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Belinostat may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Belinostat may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Belinostat may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol |
DB00376 | DB00835 | 1,105 | 100 | [
"DDInter1870",
"DDInter245"
] | Trihexyphenidyl | Brompheniramine | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects. It has largely been replaced by drugs such as [levodopa]. Trihexyphenidyl was granted FDA approval on 13 May 1949. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1105,
24,
100
]
],
[
[
1105,
24,
832
],
[
832,
24,
100
]
],
[
[
1105,
24,
649
],
[
649,
63,
100
]
],
[
[
1105,
63,
1594
],
[
1594,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennami... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trihexyphenidyl (Compound) binds CHRM4 (Gene) and CHRM4 (Gene) is bound by Brompheniramine (Compound)
Trihexyphenidyl (Compound) resembles Glycopyrronium (Compound) and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trihexyphenidyl (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trihexyphenidyl (Compound) resembles Procyclidine (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trihexyphenidyl may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Brompheniramine
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Brompheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine |
DB00813 | DB01233 | 704 | 1,311 | [
"DDInter722",
"DDInter1197"
] | Fentanyl | Metoclopramide | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and [oxycodone]. Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily. Fentanyl was FDA approved in 1968.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980. | Moderate | 1 | [
[
[
704,
24,
1311
]
],
[
[
704,
10,
11562
],
[
11562,
49,
1311
]
],
[
[
704,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
704,
24,
1383
],
[
13... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Fentanyl",
"{u} (Compound) palliates {v} (Disease)",
"prostate cancer"
],
[
"prostate cancer",
"{u} (Disease) ... | Fentanyl (Compound) palliates prostate cancer (Disease) and prostate cancer (Disease) is palliated by Metoclopramide (Compound)
Fentanyl (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Fentanyl (Compound) resembles Benzatropine (Compound) and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Fentanyl may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Fentanyl may lead to a major life threatening interaction when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Fentanyl may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide |
DB01403 | DB11186 | 9 | 1,609 | [
"DDInter1175",
"DDInter1427"
] | Methotrimeprazine | Pentoxyverine | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma-1 receptors, as well as kappa and mu-opioid receptors. The FDA withdrew the use of all oral gel drug products containing pentoxyverine citrate. Other forms of pentoxyverine citrate continue to be marketed. | Moderate | 1 | [
[
[
9,
24,
1609
]
],
[
[
9,
1,
508
],
[
508,
24,
1609
]
],
[
[
9,
64,
506
],
[
506,
24,
1609
]
],
[
[
9,
63,
662
],
[
662,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may ... | Methotrimeprazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Methotrimeprazine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Methotrimeprazine (Compound) resembles Mepyramine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Methotrimeprazine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Pentoxyverine
Methotrimeprazine (Compound) resembles Promazine (Compound) and Promazine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Methotrimeprazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine |
DB06822 | DB12500 | 802 | 283 | [
"DDInter1812",
"DDInter714"
] | Tinzaparin | Fedratinib | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
802,
25,
283
]
],
[
[
802,
64,
885
],
[
885,
24,
283
]
],
[
[
802,
63,
529
],
[
529,
24,
283
]
],
[
[
802,
25,
1618
],
[
1618,
2... | [
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{... | Tinzaparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Tinzaparin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Tinzaparin may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Fedratinib
Tinzaparin may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may lead to a major life threatening interaction when taken with Fedratinib
Tinzaparin may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Fedratinib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may lead to a major life threatening interaction when taken with Fedratinib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may lead to a major life threatening interaction when taken with Fedratinib |
DB00092 | DB06176 | 58 | 1,342 | [
"DDInter40",
"DDInter1616"
] | Alefacept | Romidepsin | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
58,
24,
1342
]
],
[
[
58,
24,
336
],
[
336,
24,
1342
]
],
[
[
58,
24,
1491
],
[
1491,
63,
1342
]
],
[
[
58,
23,
1461
],
[
1461,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Alefacept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen and Bacillus calmette-guerin substrain tice live antigen may lead to a major life threatening interaction when taken with Romidepsin
Alefacept may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Romidepsin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Romidepsin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Procainamide and Procainamide may lead to a major life threatening interaction when taken with Romidepsin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Romidepsin |
DB08901 | DB11760 | 1,468 | 119 | [
"DDInter1492",
"DDInter1742"
] | Ponatinib | Talazoparib | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306] | Moderate | 1 | [
[
[
1468,
24,
119
]
],
[
[
1468,
63,
66
],
[
66,
24,
119
]
],
[
[
1468,
64,
441
],
[
441,
24,
119
]
],
[
[
1468,
24,
1129
],
[
1129,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ponatinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ponatinib may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ponatinib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Talazoparib
Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Talazoparib
Ponatinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Talazoparib
Ponatinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Talazoparib |
DB01229 | DB14783 | 973 | 287 | [
"DDInter1378",
"DDInter574"
] | Paclitaxel (protein-bound) | Diroximel fumarate | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021. | Moderate | 1 | [
[
[
973,
24,
287
]
],
[
[
973,
63,
1101
],
[
1101,
24,
287
]
],
[
[
973,
24,
384
],
[
384,
24,
287
]
],
[
[
973,
64,
770
],
[
770,
2... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Paclitaxel may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate
Paclitaxel may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Diroximel fumarate
Paclitaxel may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Diroximel fumarate
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Diroximel fumarate
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate |
DB01611 | DB06595 | 1,487 | 1,491 | [
"DDInter893",
"DDInter1214"
] | Hydroxychloroquine | Midostaurin | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Major | 2 | [
[
[
1487,
25,
1491
]
],
[
[
1487,
63,
112
],
[
112,
23,
1491
]
],
[
[
1487,
62,
1247
],
[
1247,
23,
1491
]
],
[
[
1487,
64,
888
],
[
888,
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Hydroxychloroquine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Hydroxychloroquine may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Hydroxychloroquine may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin |
DB00425 | DB00673 | 558 | 723 | [
"DDInter1970",
"DDInter112"
] | Zolpidem | Aprepitant | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is available in both immediate acting and extended release forms [FDA label],. Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. This drug has the propensity to completely or partially | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV). | Moderate | 1 | [
[
[
558,
24,
723
]
],
[
[
558,
6,
7950
],
[
7950,
45,
723
]
],
[
[
558,
21,
28890
],
[
28890,
60,
723
]
],
[
[
558,
24,
222
],
[
222,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Zolpidem (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Zolpidem (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Aprepitant (Compound)
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Aprepitant
Zolpidem (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Aprepitant |
DB00264 | DB05812 | 88 | 1,374 | [
"DDInter1200",
"DDInter8"
] | Metoprolol | Abiraterone | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835] | Moderate | 1 | [
[
[
88,
24,
1374
]
],
[
[
88,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
88,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
88,
24,
760
],
[
760,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Metoprolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Metoprolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Metoprolol (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Metoprolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Abiraterone |
DB00220 | DB00889 | 798 | 1,133 | [
"DDInter1276",
"DDInter840"
] | Nelfinavir | Granisetron | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
798,
24,
1133
]
],
[
[
798,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
798,
7,
8386
],
[
8386,
57,
1133
]
],
[
[
798,
21,
28851
],
[
28851,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Nelfinavir (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Granisetron (Compound)
Nelfinavir (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is caused by Granisetron (Compound)
Nelfinavir may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Nelfinavir may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Granisetron
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Granisetron |
DB00514 | DB01233 | 506 | 1,311 | [
"DDInter527",
"DDInter1197"
] | Dextromethorphan | Metoclopramide | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures. One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route. Metoclopramide was initially approved by the FDA in 1980. | Moderate | 1 | [
[
[
506,
24,
1311
]
],
[
[
506,
6,
12523
],
[
12523,
45,
1311
]
],
[
[
506,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
506,
24,
1020
],
[
102... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by ... | Dextromethorphan (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoclopramide (Compound)
Dextromethorphan (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Dextromethorphan may lead to a major life threatening interaction when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Dextromethorphan may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Dextromethorphan may lead to a major life threatening interaction when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Dextromethorphan (Compound) resembles Dezocine (Compound) and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide |
DB00366 | DB00647 | 1,594 | 675 | [
"DDInter600",
"DDInter528"
] | Doxylamine | Dextropropoxyphene | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect. | Major | 2 | [
[
[
1594,
36,
675
]
],
[
[
1594,
40,
888
],
[
888,
64,
675
]
],
[
[
1594,
74,
494
],
[
494,
1,
675
]
],
[
[
1594,
24,
1511
],
[
1511,
... | [
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxif... | Doxylamine (Compound) resembles Dextropropoxyphene (Compound) and
Doxylamine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene
Doxylamine (Compound) resembles Disopyramide (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Dextropropoxyphene (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Dextropropoxyphene (Compound)
Doxylamine (Compound) resembles Levacetylmethadol (Compound) and Doxylamine may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Dextropropoxyphene (Compound)
Doxylamine (Compound) resembles Methadyl Acetate (Compound) and Methadyl Acetate (Compound) resembles Dextropropoxyphene (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may lead to a major life threatening interaction when taken with Dextropropoxyphene
Doxylamine (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Dextropropoxyphene (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene |
DB00222 | DB00774 | 245 | 1,577 | [
"DDInter825",
"DDInter889"
] | Glimepiride | Hydroflumethiazide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
245,
24,
1577
]
],
[
[
245,
24,
359
],
[
359,
40,
1577
]
],
[
[
245,
24,
504
],
[
504,
1,
1577
]
],
[
[
245,
21,
29455
],
[
29455,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Glimepiride (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Hydroflumethiazide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Hydroflumethiazide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide |
DB00372 | DB00373 | 999 | 461 | [
"DDInter1793",
"DDInter1809"
] | Thiethylperazine | Timolol | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension. | Moderate | 1 | [
[
[
999,
24,
461
]
],
[
[
999,
23,
1283
],
[
1283,
62,
461
]
],
[
[
999,
62,
417
],
[
417,
23,
461
]
],
[
[
999,
24,
1450
],
[
1450,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
... | Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Timolol
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Timolol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Thiethylperazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Timolol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Timolol
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound) |
DB00414 | DB00968 | 590 | 1,551 | [
"DDInter16",
"DDInter1185"
] | Acetohexamide | Methyldopa | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since then, methyldopa was largely replaced by newer, better-tolerated antihypertensive agents; however, it is still used as monotherapy or in combination with [hydrochlorothiazide]. Methyldopa is also available as intravenous injection, which is used to manage hypertension when oral therapy is unfeasible and to treat hypertensive crisis. | Minor | 0 | [
[
[
590,
23,
1551
]
],
[
[
590,
24,
817
],
[
817,
40,
1551
]
],
[
[
590,
24,
874
],
[
874,
24,
1551
]
],
[
[
590,
24,
1264
],
[
1264,
... | [
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methyldopa"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Methyldopa (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Methyldopa
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Methyldopa
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Methyldopa
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Norepinephrine (Compound) and Norepinephrine (Compound) resembles Methyldopa (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline (Compound) resembles Norepinephrine (Compound) and Norepinephrine (Compound) resembles Methyldopa (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Dopamine and Dopamine (Compound) resembles Methyldopa (Compound) |
DB00348 | DB00599 | 254 | 682 | [
"DDInter1300",
"DDInter1795"
] | Nitisinone | Thiopental | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does not produce any excitation but has poor analgesic and muscle relaxant properties. Small doses have been shown to be anti-analgesic and lower the pain threshold. (From Martindale, The Extra Pharmacopoeia, 30th ed, p920) | Moderate | 1 | [
[
[
254,
24,
682
]
],
[
[
254,
63,
1023
],
[
1023,
1,
682
]
],
[
[
254,
24,
536
],
[
536,
1,
682
]
],
[
[
254,
24,
752
],
[
752,
23,... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
[... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Thiopental (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Thiopental (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Thiopental
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Thiopental
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Thiopental
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Thiopental
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Thiopental
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) resembles Thiopental (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) resembles Thiopental (Compound) |
DB00620 | DB06819 | 175 | 754 | [
"DDInter1855",
"DDInter1452"
] | Triamcinolone | Phenylbutyric acid | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular | Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone. It is used to treat genetic metabolic syndromes, neuropathies, and urea cycle disorders.[L386,L42105] | Moderate | 1 | [
[
[
175,
24,
754
]
],
[
[
175,
40,
891
],
[
891,
24,
754
]
],
[
[
175,
63,
1236
],
[
1236,
24,
754
]
],
[
[
175,
24,
697
],
[
697,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutyric acid"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} m... | Triamcinolone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone (Compound) resembles Prednisolone (Compound) and Prednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone (Compound) resembles Betamethasone (Compound) and Betamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone (Compound) resembles Budesonide (Compound) and Budesonide (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid |
DB00015 | DB01166 | 582 | 477 | [
"DDInter1585",
"DDInter379"
] | Reteplase | Cilostazol | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
582,
24,
477
]
],
[
[
582,
23,
297
],
[
297,
62,
477
]
],
[
[
582,
25,
126
],
[
126,
23,
477
]
],
[
[
582,
24,
109
],
[
109,
24,... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clov... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Reteplase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Reteplase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Reteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Reteplase may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Cilostazol
Reteplase may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Cilostazol
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Cilostazol |
DB06715 | DB13074 | 239 | 877 | [
"DDInter1500",
"DDInter1110"
] | Potassium Iodide | Macimorelin | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Moderate | 1 | [
[
[
239,
24,
877
]
],
[
[
239,
63,
1171
],
[
1171,
24,
877
]
],
[
[
239,
24,
116
],
[
116,
24,
877
]
],
[
[
239,
24,
1399
],
[
1399,
... | [
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
... | Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may lead to a major life threatening interaction when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may lead to a major life threatening interaction when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Clonidine (Compound) and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin |
DB00834 | DB14568 | 932 | 982 | [
"DDInter1215",
"DDInter1000"
] | Mifepristone | Ivosidenib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA in July 2018 for the treatment of relapsed of refractory acute myeloid leukemia in adults. It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma and relapsed or refractory myelodysplastic syndromes in adults. The drug is only effective in patients with a susceptible IDH1 mutation. In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment of acute myeloid leukemia and cholangiocarcinoma. It was fully approved by the EMA in May 2023. | Major | 2 | [
[
[
932,
25,
982
]
],
[
[
932,
23,
112
],
[
112,
23,
982
]
],
[
[
932,
63,
168
],
[
168,
23,
982
]
],
[
[
932,
62,
1101
],
[
1101,
2... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Mifepristone may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Mifepristone may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Mifepristone may lead to a major life threatening interaction when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Mifepristone may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Ivosidenib |
DB00744 | DB09122 | 1,288 | 1,613 | [
"DDInter1962",
"DDInter1409"
] | Zileuton | Peginterferon beta-1a | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792] Peginterferon beta-1a is an interferon therapy used for the management of relapsing forms of MS. It was originally approved by the FDA in 2014 for subcutaneous use, and was approved for intramuscular use in January 2021. Currently, it is the only approved pegylated interferon for the management of MS with an proven ability to reduce relapses and delay the progression of disability resulting from MS. | Moderate | 1 | [
[
[
1288,
24,
1613
]
],
[
[
1288,
63,
267
],
[
267,
24,
1613
]
],
[
[
1288,
24,
351
],
[
351,
63,
1613
]
],
[
[
1288,
24,
478
],
[
478,
... | [
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Zileuton may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Zileuton may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a |
DB00213 | DB01583 | 837 | 624 | [
"DDInter1388",
"DDInter1075"
] | Pantoprazole | Liotrix | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion. It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues. Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage. In fact, administration of T3 may result in supratherapeutic levels of T3. | Moderate | 1 | [
[
[
837,
24,
624
]
],
[
[
837,
24,
1152
],
[
1152,
1,
624
]
],
[
[
837,
24,
542
],
[
542,
40,
624
]
],
[
[
837,
6,
15333
],
[
15333,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Compound)
Pantoprazole (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Liotrix (Compound)
Pantoprazole (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Liotrix (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Liotrix
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Iron and Iron may cause a moderate interaction that could exacerbate diseases when taken with Liotrix |
DB00500 | DB00635 | 24 | 1,573 | [
"DDInter1831",
"DDInter1515"
] | Tolmetin | Prednisone | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
24,
24,
1573
]
],
[
[
24,
24,
175
],
[
175,
40,
1573
]
],
[
[
24,
63,
251
],
[
251,
1,
1573
]
],
[
[
24,
24,
167
],
[
167,
1,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Prednisone (Compound)
Tolmetin (Compound) palliates ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Prednisone (Compound)
Tolmetin (Compound) palliates osteoarthritis (Disease) and osteoarthritis (Disease) is palliated by Prednisone (Compound)
Tolmetin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Prednisone (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Prednisone
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone
Tolmetin (Compound) resembles Ketorolac (Compound) and Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Prednisone |
DB08865 | DB14575 | 1,593 | 733 | [
"DDInter448",
"DDInter674"
] | Crizotinib | Eslicarbazepine | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1593,
24,
733
]
],
[
[
1593,
63,
1101
],
[
1101,
23,
733
]
],
[
[
1593,
64,
1264
],
[
1264,
24,
733
]
],
[
[
1593,
25,
1135
],
[
1135,... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Crizotinib may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Crizotinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Crizotinib may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Eslicarbazepine
Crizotinib may lead to a major life threatening interaction when taken with Cobimetinib and Cobimetinib may lead to a major life threatening interaction when taken with Eslicarbazepine |
DB06603 | DB11952 | 39 | 800 | [
"DDInter1387",
"DDInter612"
] | Panobinostat | Duvelisib | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018. | Moderate | 1 | [
[
[
39,
24,
800
]
],
[
[
39,
63,
663
],
[
663,
24,
800
]
],
[
[
39,
24,
270
],
[
270,
63,
800
]
],
[
[
39,
64,
11
],
[
11,
24,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Panobinostat may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Panobinostat may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Panobinostat may lead to a major life threatening interaction when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Panobinostat may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib
Panobinostat may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Duvelisib
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Duvelisib |
DB00468 | DB01339 | 1,424 | 728 | [
"DDInter1557",
"DDInter1922"
] | Quinine | Vecuronium | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. | Moderate | 1 | [
[
[
1424,
24,
728
]
],
[
[
1424,
24,
1610
],
[
1610,
1,
728
]
],
[
[
1424,
24,
1579
],
[
1579,
40,
728
]
],
[
[
1424,
6,
4973
],
[
4973,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
[
"R... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Vecuronium (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (Compound)
Quinine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Vecuronium (Compound)
Quinine (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Vecuronium (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium
Quinine may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Pipecuronium (Compound) and Pipecuronium (Compound) resembles Vecuronium (Compound) |
DB00834 | DB09078 | 932 | 1,228 | [
"DDInter1215",
"DDInter1036"
] | Mifepristone | Lenvatinib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials). | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Major | 2 | [
[
[
932,
25,
1228
]
],
[
[
932,
23,
112
],
[
112,
23,
1228
]
],
[
[
932,
25,
609
],
[
609,
24,
1228
]
],
[
[
932,
24,
770
],
[
770,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Mifepristone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mifepristone may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mifepristone may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mifepristone may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib
Mifepristone may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Lenvatinib |
DB00281 | DB00877 | 608 | 629 | [
"DDInter1066",
"DDInter1678"
] | Lidocaine | Sirolimus | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex. | Moderate | 1 | [
[
[
608,
24,
629
]
],
[
[
608,
6,
4973
],
[
4973,
45,
629
]
],
[
[
608,
18,
15501
],
[
15501,
57,
629
]
],
[
[
608,
21,
29276
],
[
29276,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Lidocaine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Sirolimus (Compound)
Lidocaine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Sirolimus (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Sulfinpyrazone and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Albendazole and Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Nevirapine and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus |
DB01069 | DB01192 | 401 | 560 | [
"DDInter1533",
"DDInter1372"
] | Promethazine | Oxymorphone | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. | Moderate | 1 | [
[
[
401,
24,
560
]
],
[
[
401,
63,
828
],
[
828,
1,
560
]
],
[
[
401,
6,
12523
],
[
12523,
45,
560
]
],
[
[
401,
21,
28817
],
[
28817,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Oxymorphone (Compound)
Promethazine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Oxymorphone (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone
Promethazine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone
Promethazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Oxymorphone
Promethazine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Oxymorphone |
DB00682 | DB06701 | 126 | 1,177 | [
"DDInter1951",
"DDInter521"
] | Warfarin | Dexmethylphenidate | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture. | Minor | 0 | [
[
[
126,
23,
1177
]
],
[
[
126,
62,
895
],
[
895,
1,
1177
]
],
[
[
126,
24,
1264
],
[
1264,
24,
1177
]
],
[
[
126,
23,
1053
],
[
1053,
... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexmethylphenidate"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylphenidate"
],
... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Methylphenidate and Methylphenidate (Compound) resembles Dexmethylphenidate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Dexmethylphenidate
Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Dexmethylphenidate
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Dexmethylphenidate
Warfarin may cause a minor interaction that can limit clinical effects when taken with Methylphenidate and Methylphenidate (Compound) resembles Cyclopentolate (Compound) and Cyclopentolate (Compound) resembles Dexmethylphenidate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Methylphenidate and Methylphenidate (Compound) resembles Dexmethylphenidate (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Methylphenidate and Methylphenidate (Compound) resembles Dexmethylphenidate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine (Compound) resembles Cyclopentolate (Compound) and Cyclopentolate (Compound) resembles Dexmethylphenidate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Methylphenidate and Methylphenidate (Compound) resembles Dexmethylphenidate (Compound) |
DB00694 | DB11730 | 51 | 351 | [
"DDInter485",
"DDInter1588"
] | Daunorubicin | Ribociclib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
51,
25,
351
]
],
[
[
51,
24,
466
],
[
466,
62,
351
]
],
[
[
51,
23,
1247
],
[
1247,
23,
351
]
],
[
[
51,
24,
479
],
[
479,
23,
... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daro... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin and Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Daunorubicin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib |
DB00468 | DB00728 | 1,424 | 1,610 | [
"DDInter1557",
"DDInter1612"
] | Quinine | Rocuronium | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. [Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium. | Moderate | 1 | [
[
[
1424,
24,
1610
]
],
[
[
1424,
24,
728
],
[
728,
40,
1610
]
],
[
[
1424,
6,
6648
],
[
6648,
45,
1610
]
],
[
[
1424,
21,
29118
],
[
2911... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
],
[
"V... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Rocuronium (Compound)
Quinine (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Rocuronium (Compound)
Quinine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Rocuronium (Compound)
Quinine may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium
Quinine may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Pancuronium (Compound) and Pancuronium (Compound) resembles Rocuronium (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (Compound) and Vecuronium (Compound) resembles Rocuronium (Compound) |
DB06448 | DB06595 | 171 | 1,491 | [
"DDInter1087",
"DDInter1214"
] | Lonafarnib | Midostaurin | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FT | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Major | 2 | [
[
[
171,
25,
1491
]
],
[
[
171,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
171,
63,
112
],
[
112,
23,
1491
]
],
[
[
171,
63,
761
],
[
761,
... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} ma... | Lonafarnib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Lonafarnib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Lonafarnib may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Lonafarnib may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Midostaurin
Lonafarnib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Midostaurin |
DB06772 | DB10989 | 310 | 496 | [
"DDInter259",
"DDInter858"
] | Cabazitaxel | Hepatitis A Vaccine | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrier compared to other taxanes like [paclitaxel] and [docetaxel].[A7056, A260421, A260621] Cabazitaxel is used to treat metastatic castration-resistant prostate cancer. It was first approved by the FDA on June 17, 2010. It was also approved by the EMA on March 17, 2011 and Health Canada on December 17, 2019. | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries. | Moderate | 1 | [
[
[
310,
24,
496
]
],
[
[
310,
63,
4
],
[
4,
24,
496
]
],
[
[
310,
24,
850
],
[
850,
24,
496
]
],
[
[
310,
24,
738
],
[
738,
63,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine |
DB00425 | DB00835 | 558 | 100 | [
"DDInter1970",
"DDInter245"
] | Zolpidem | Brompheniramine | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia. It is available in both immediate acting and extended release forms [FDA label],. Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. This drug has the propensity to completely or partially | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
558,
24,
100
]
],
[
[
558,
24,
832
],
[
832,
24,
100
]
],
[
[
558,
63,
128
],
[
128,
24,
100
]
],
[
[
558,
24,
649
],
[
649,
63,... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Zolpidem (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Brompheniramine (Compound)
Zolpidem may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Brompheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Brompheniramine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine |
DB00674 | DB01041 | 1,516 | 770 | [
"DDInter802",
"DDInter1789"
] | Galantamine | Thalidomide | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | Moderate | 1 | [
[
[
1516,
24,
770
]
],
[
[
1516,
21,
29425
],
[
29425,
60,
770
]
],
[
[
1516,
24,
609
],
[
609,
63,
770
]
],
[
[
1516,
63,
1557
],
[
1557,... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial ischaemia"
],
[
"Myocardial ischaemia",
"... | Galantamine (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Thalidomide (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Galantamine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Thalidomide
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may lead to a major life threatening interaction when taken with Thalidomide
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Thalidomide
Galantamine (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Thalidomide (Compound) |
DB00067 | DB12245 | 317 | 823 | [
"DDInter1921",
"DDInter1863"
] | Vasopressin | Triclabendazole | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V<sub>1</sub> and V<sub>2</sub> cellular receptors.[A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Moderate | 1 | [
[
[
317,
24,
823
]
],
[
[
317,
23,
112
],
[
112,
23,
823
]
],
[
[
317,
24,
1010
],
[
1010,
24,
823
]
],
[
[
317,
24,
1619
],
[
1619,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Vasopressin may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Vasopressin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Triclabendazole
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole |
DB00446 | DB01042 | 597 | 1,307 | [
"DDInter351",
"DDInter1144"
] | Chloramphenicol | Melphalan | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases. | Moderate | 1 | [
[
[
597,
24,
1307
]
],
[
[
597,
24,
1191
],
[
1191,
1,
1307
]
],
[
[
597,
21,
29232
],
[
29232,
60,
1307
]
],
[
[
597,
63,
168
],
[
168,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
],
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Melphalan (Compound)
Chloramphenicol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Melphalan (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Chloramphenicol may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Melphalan
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Melphalan |
DB00860 | DB00963 | 891 | 1,263 | [
"DDInter1513",
"DDInter241"
] | Prednisolone | Bromfenac | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes. Non-ophthalmic formulations of bromfenac were withdrawn in the US in 1998 due to cases of severe liver toxicity.[L43942,T239] | Moderate | 1 | [
[
[
891,
24,
1263
]
],
[
[
891,
24,
935
],
[
935,
40,
1263
]
],
[
[
891,
63,
831
],
[
831,
40,
1263
]
],
[
[
891,
63,
1512
],
[
1512,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Bromfenac (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Prednisolone (Compound) causes Sensation of foreign body (Side Effect) and Sensation of foreign body (Side Effect) is caused by Bromfenac (Compound)
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Bromfenac
Prednisolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac |
DB00372 | DB00692 | 999 | 274 | [
"DDInter1793",
"DDInter1448"
] | Thiethylperazine | Phentolamine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[A261781, A261786] It has several therapeutic uses, including the treatment of hypertensive episodes, prevention of norepinephrine-induced extravasation, diagnosis of pheochromocytoma, reversal of soft-tissue anesthesia, and treatment of pharmacologically-induced mydriasis.[L48420, L48415, L48390] Phentolamine is administered intravenously, intramuscularly, submucosally, and topically. | Moderate | 1 | [
[
[
999,
24,
274
]
],
[
[
999,
24,
1296
],
[
1296,
62,
274
]
],
[
[
999,
63,
1179
],
[
1179,
23,
274
]
],
[
[
999,
63,
695
],
[
695,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin deglu... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a minor interaction that can limit clinical effects when taken with Phentolamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Phentolamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam and Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Thiethylperazine may lead to a major life threatening interaction when taken with Tetrabenazine and Tetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Thiethylperazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Phentolamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine |
DB01278 | DB12015 | 1,021 | 1,033 | [
"DDInter1506",
"DDInter53"
] | Pramlintide | Alpelisib | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
1021,
24,
1033
]
],
[
[
1021,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
1021,
63,
1144
],
[
1144,
24,
1033
]
],
[
[
1021,
24,
1654
],
[
16... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may lead to a major life threatening interaction when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib |
DB00108 | DB00601 | 1,066 | 453 | [
"DDInter1268",
"DDInter1073"
] | Natalizumab | Linezolid | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023. | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor. | Major | 2 | [
[
[
1066,
25,
453
]
],
[
[
1066,
25,
770
],
[
770,
63,
453
]
],
[
[
1066,
24,
1430
],
[
1430,
63,
453
]
],
[
[
1066,
25,
168
],
[
168,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Linezolid"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u... | Natalizumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Linezolid
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Linezolid
Natalizumab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Linezolid
Natalizumab may lead to a major life threatening interaction when taken with Interferon alfa-n1 and Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Linezolid
Natalizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Linezolid
Natalizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Linezolid
Natalizumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Linezolid
Natalizumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Linezolid (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Linezolid |
DB08816 | DB09054 | 578 | 384 | [
"DDInter1802",
"DDInter905"
] | Ticagrelor | Idelalisib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Major | 2 | [
[
[
578,
25,
384
]
],
[
[
578,
63,
222
],
[
222,
23,
384
]
],
[
[
578,
24,
555
],
[
555,
23,
384
]
],
[
[
578,
23,
907
],
[
907,
62,... | [
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ticagrelor may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib and Erdafitinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ticagrelor may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib |
DB00334 | DB01064 | 867 | 1,148 | [
"DDInter1326",
"DDInter987"
] | Olanzapine | Isoprenaline | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Moderate | 1 | [
[
[
867,
24,
1148
]
],
[
[
867,
24,
480
],
[
480,
24,
1148
]
],
[
[
867,
7,
5178
],
[
5178,
46,
1148
]
],
[
[
867,
18,
6929
],
[
6929,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Olanzapine (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is upregulated by Isoprenaline (Compound)
Olanzapine (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is downregulated by Isoprenaline (Compound)
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Olanzapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Olanzapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Isoprenaline
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Isoprenaline |
DB00976 | DB01254 | 1,056 | 1,213 | [
"DDInter1758",
"DDInter484"
] | Telithromycin | Dasatinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections. | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Major | 2 | [
[
[
1056,
25,
1213
]
],
[
[
1056,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
1056,
21,
28956
],
[
28956,
60,
1213
]
],
[
[
1056,
62,
112
],
[
11... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Da... | Telithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Telithromycin (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Dasatinib (Compound)
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Telithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Dasatinib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Telithromycin may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Telithromycin may lead to a major life threatening interaction when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB00559 | DB08901 | 152 | 1,468 | [
"DDInter223",
"DDInter1492"
] | Bosentan | Ponatinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
152,
24,
1468
]
],
[
[
152,
24,
478
],
[
478,
24,
1468
]
],
[
[
152,
6,
10083
],
[
10083,
45,
1468
]
],
[
[
152,
18,
5795
],
[
5795,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"N... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Bosentan (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Ponatinib (Compound)
Bosentan (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is downregulated by Ponatinib (Compound)
Bosentan (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Ponatinib (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Bosentan may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib |
DB00014 | DB00738 | 521 | 485 | [
"DDInter839",
"DDInter1420"
] | Goserelin | Pentamidine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
521,
24,
485
]
],
[
[
521,
21,
28981
],
[
28981,
60,
485
]
],
[
[
521,
23,
1247
],
[
1247,
62,
485
]
],
[
[
521,
24,
971
],
[
971,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Renal impairment"
],
[
"Renal impairment",
"{u} (Side Ef... | Goserelin (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Pentamidine (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Pentamidine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Galantamine and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Goserelin (Compound) resembles Degarelix (Compound) and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine
Goserelin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Pentamidine
Goserelin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Pentamidine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may lead to a major life threatening interaction when taken with Pentamidine
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Pentamidine |
DB00860 | DB01390 | 891 | 1,117 | [
"DDInter1513",
"DDInter1683"
] | Prednisolone | Sodium bicarbonate | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
891,
23,
1117
]
],
[
[
891,
21,
28778
],
[
28778,
60,
1117
]
],
[
[
891,
40,
1220
],
[
1220,
23,
1117
]
],
[
[
891,
62,
1018
],
[
1018... | [
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
... | Prednisolone (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Sodium bicarbonate (Compound)
Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Prednisolone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate |
DB00836 | DB11978 | 543 | 124 | [
"DDInter1088",
"DDInter822"
] | Loperamide | Glasdegib | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile. | Moderate | 1 | [
[
[
543,
24,
124
]
],
[
[
543,
24,
112
],
[
112,
23,
124
]
],
[
[
543,
24,
1079
],
[
1079,
24,
124
]
],
[
[
543,
63,
475
],
[
475,
2... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Loperamide may lead to a major life threatening interaction when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Loperamide may lead to a major life threatening interaction when taken with Fosamprenavir and Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Loperamide (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may lead to a major life threatening interaction when taken with Glasdegib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Glasdegib |
DB03904 | DB14509 | 1,574 | 1,399 | [
"DDInter1903",
"DDInter1081"
] | Urea | Lithium carbonate | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Minor | 0 | [
[
[
1574,
23,
1399
]
],
[
[
1574,
24,
1344
],
[
1344,
24,
1399
]
],
[
[
1574,
63,
123
],
[
123,
24,
1399
]
],
[
[
1574,
24,
1527
],
[
1527... | [
[
[
"Urea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Urea may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate and Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate |
DB00907 | DB01168 | 290 | 1,053 | [
"DDInter427",
"DDInter1526"
] | Cocaine (topical) | Procarbazine | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
290,
25,
1053
]
],
[
[
290,
21,
28975
],
[
28975,
60,
1053
]
],
[
[
290,
63,
839
],
[
839,
23,
1053
]
],
[
[
290,
25,
480
],
[
480,
... | [
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Cocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Cocaine may lead to a major life threatening interaction when taken with Procarbazine
Cocaine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Procarbazine (Compound)
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Cocaine may lead to a major life threatening interaction when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Cocaine may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Cocaine may lead to a major life threatening interaction when taken with Reserpine and Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Isosorbide dinitrate and Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Isosorbide mononitrate and Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine
Cocaine may lead to a major life threatening interaction when taken with Dopamine and Dopamine may lead to a major life threatening interaction when taken with Procarbazine |
DB00532 | DB11767 | 208 | 1,583 | [
"DDInter1152",
"DDInter1643"
] | Mephenytoin | Sarilumab | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incid | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms. | Moderate | 1 | [
[
[
208,
24,
1583
]
],
[
[
208,
24,
267
],
[
267,
24,
1583
]
],
[
[
208,
63,
482
],
[
482,
24,
1583
]
],
[
[
208,
24,
270
],
[
270,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Mephenytoin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sarilumab
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Sarilumab
Mephenytoin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Sarilumab
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab |
DB01234 | DB11714 | 1,220 | 1,316 | [
"DDInter513",
"DDInter610"
] | Dexamethasone | Durvalumab | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.[L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy.[A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). | Moderate | 1 | [
[
[
1220,
24,
1316
]
],
[
[
1220,
62,
1461
],
[
1461,
23,
1316
]
],
[
[
1220,
23,
1114
],
[
1114,
23,
1316
]
],
[
[
1220,
40,
167
],
[
167... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Dexamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Dexamethasone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab
Dexamethasone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Durvalumab |
DB00745 | DB11581 | 307 | 1,456 | [
"DDInter1236",
"DDInter1926"
] | Modafinil | Venetoclax | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy [FDA label]. Previously, this drug was indicated only for patients with 17p gene deletion . | Major | 2 | [
[
[
307,
25,
1456
]
],
[
[
307,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
307,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
307,
23,
86
],
[
86,
... | [
[
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Modafinil may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Modafinil may cause a minor interaction that can limit clinical effects when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Modafinil may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Modafinil may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Modafinil (Compound) resembles Warfarin (Compound) and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax
Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax |
DB01069 | DB11160 | 401 | 337 | [
"DDInter1533",
"DDInter1459"
] | Promethazine | Phenyltoloxamine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the more common salt form that acts as an active ingredient in pharmaceutical products and promotes hay fever relief via reversing the effects of histamine. Phenyltoloxamine acts as an adjuvant analgesic, which augments the analgesic effect of acetaminophen. It also potentiates the effects of other drugs, such as codeine and codeine derivatives. Although phenyltoloxamine's ability to potentiate the effects of analgesics may be explained in part by its chemical nature as a first-generation H1 antihistamine that is capable of crossing the blood-brain barrier and causing tranquilizing effects at CNS histamine receptors, many of the drug's specific pharmacokinetics are not readily available - perhaps also because many early (phenyltoloxamine was involved in studies as early as the 1950s) first-generation antihistamines were not optimally investigated . Nevertheless, phenyltoloxamine is used to a fairly limited extent in contemporary medicine, with only very few products involving it as an active ingredient. | Moderate | 1 | [
[
[
401,
24,
337
]
],
[
[
401,
23,
771
],
[
771,
62,
337
]
],
[
[
401,
24,
820
],
[
820,
24,
337
]
],
[
[
401,
63,
999
],
[
999,
24,... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
... | Promethazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Promethazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Promethazine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may lead to a major life threatening interaction when taken with Phenyltoloxamine
Promethazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Phenyltoloxamine |
DB00018 | DB00531 | 199 | 450 | [
"DDInter945",
"DDInter456"
] | Interferon alfa-n3 | Cyclophosphamide | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. | Minor | 0 | [
[
[
199,
23,
450
]
],
[
[
199,
24,
270
],
[
270,
63,
450
]
],
[
[
199,
25,
1648
],
[
1648,
24,
450
]
],
[
[
199,
25,
593
],
[
593,
6... | [
[
[
"Interferon alfa-n3",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocreliz... | Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Cyclophosphamide
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine (Compound) resembles Cyclophosphamide (Compound)
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine (Compound) resembles Cyclophosphamide (Compound)
Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine and Mechlorethamine (Compound) resembles Cyclophosphamide (Compound)
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Bupropion and Bupropion (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cyclophosphamide (Compound) |
DB11757 | DB12141 | 960 | 971 | [
"DDInter994",
"DDInter817"
] | Istradefylline | Gilteritinib | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
960,
24,
971
]
],
[
[
960,
62,
1135
],
[
1135,
23,
971
]
],
[
[
960,
63,
1181
],
[
1181,
24,
971
]
],
[
[
960,
24,
283
],
[
283,
... | [
[
[
"Istradefylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Istradefylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
... | Istradefylline may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Istradefylline may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Istradefylline may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Gilteritinib
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may lead to a major life threatening interaction when taken with Gilteritinib
Istradefylline may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Gilteritinib
Istradefylline may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib |
DB00427 | DB01242 | 1,233 | 1,237 | [
"DDInter1879",
"DDInter410"
] | Triprolidine | Clomipramine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine. | Moderate | 1 | [
[
[
1233,
24,
1237
]
],
[
[
1233,
24,
684
],
[
684,
1,
1237
]
],
[
[
1233,
63,
902
],
[
902,
40,
1237
]
],
[
[
1233,
24,
272
],
[
272,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clomipramine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Clomipramine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Clomipramine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Triprolidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Clomipramine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Clomipramine |
DB01118 | DB11767 | 33 | 1,583 | [
"DDInter76",
"DDInter1643"
] | Amiodarone | Sarilumab | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286] | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms. | Moderate | 1 | [
[
[
33,
24,
1583
]
],
[
[
33,
63,
267
],
[
267,
24,
1583
]
],
[
[
33,
24,
850
],
[
850,
24,
1583
]
],
[
[
33,
24,
738
],
[
738,
63,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Amiodarone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Amiodarone may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab
Amiodarone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Sarilumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Sarilumab
Amiodarone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Sarilumab |
DB00802 | DB01181 | 1,322 | 1,532 | [
"DDInter43",
"DDInter906"
] | Alfentanil | Ifosfamide | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1322,
24,
1532
]
],
[
[
1322,
6,
7524
],
[
7524,
45,
1532
]
],
[
[
1322,
21,
28792
],
[
28792,
60,
1532
]
],
[
[
1322,
63,
1648
],
[
1... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",... | Alfentanil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound)
Alfentanil (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Ifosfamide (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Alfentanil (Compound) resembles Remifentanil (Compound) and Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Alfentanil may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Alfentanil may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Alfentanil may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Ifosfamide |
DB00911 | DB15093 | 458 | 1,654 | [
"DDInter1811",
"DDInter1698"
] | Tinidazole | Somapacitan | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020. | Moderate | 1 | [
[
[
458,
24,
1654
]
],
[
[
458,
63,
168
],
[
168,
23,
1654
]
],
[
[
458,
63,
10
],
[
10,
24,
1654
]
],
[
[
458,
24,
351
],
[
351,
24... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somapacitan |
DB00005 | DB00888 | 1,057 | 1,001 | [
"DDInter687",
"DDInter1133"
] | Etanercept | Mechlorethamine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval for the orphan drug Valchlor (mechlorethamine) gel on August 23, 2013 for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (CTCL) in patients who have received prior skin-directed therapy. Each tube of Valchlor contains 0.016% of mechlorethamine which is equivalent to 0.02% mechlorethamine HCl. | Major | 2 | [
[
[
1057,
25,
1001
]
],
[
[
1057,
25,
450
],
[
450,
1,
1001
]
],
[
[
1057,
24,
126
],
[
126,
23,
1001
]
],
[
[
1057,
25,
51
],
[
51,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphami... | Etanercept may lead to a major life threatening interaction when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Mechlorethamine
Etanercept may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine
Etanercept may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Mechlorethamine
Etanercept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Mechlorethamine |
DB00421 | DB11130 | 443 | 407 | [
"DDInter1707",
"DDInter1344"
] | Spironolactone | Opium | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243, L6187] | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papaver somniferum_, which is more known as poppies. This plant is an integrant of the Papaveraceae family, and it is characterized by solitary leaves and capsulated fruits. Therefore, opium is a sticky brown resin obtained by collecting and drying the latex that exudes from the poppy pods. Once extracted, opium contains two main groups of alkaloids; the psychoactive constituents which are in the category of phenanthrenes and alkaloids that have no central nervous system effect in the category of isoquinolines. Morphine is the most prevalent and principal alkaloid in opium, and it is responsible for most of the harmful effects of opium. Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics. Some of the isolated derivatives of opium are morphine, noscapine, strychnine, veratrine, colchicine, codeine, and quinine. Opium is a prohibited drug of abuse in most countries, but the illegal production of this drug and its derivatives keeps being registered. There is some legal production of opium in different countries for the obtention of alkaloids by extraction. | Moderate | 1 | [
[
[
443,
24,
407
]
],
[
[
443,
24,
104
],
[
104,
24,
407
]
],
[
[
443,
63,
1648
],
[
1648,
24,
407
]
],
[
[
443,
25,
543
],
[
543,
2... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Opium
Spironolactone may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Opium
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Opium
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Spironolactone may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium |
DB00377 | DB01232 | 1,494 | 1,327 | [
"DDInter1382",
"DDInter1640"
] | Palonosetron | Saquinavir | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] | Major | 2 | [
[
[
1494,
25,
1327
]
],
[
[
1494,
24,
833
],
[
833,
1,
1327
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
1327
]
],
[
[
1494,
21,
28691
],
[
28691... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
],
[
"Lopinav... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) resembles Saquinavir (Compound)
Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saquinavir (Compound)
Palonosetron (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Saquinavir (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Saquinavir
Palonosetron may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Saquinavir
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir
Palonosetron may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Saquinavir
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may lead to a major life threatening interaction when taken with Saquinavir |
DB01404 | DB04932 | 757 | 1,564 | [
"DDInter820",
"DDInter491"
] | Ginseng | Defibrotide | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio. | Moderate | 1 | [
[
[
757,
24,
1564
]
],
[
[
757,
63,
1347
],
[
1347,
25,
1564
]
],
[
[
757,
24,
802
],
[
802,
64,
1564
]
],
[
[
757,
63,
1347
],
[
1347,
... | [
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
... | Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin and Tinzaparin may lead to a major life threatening interaction when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin and Tinzaparin may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Defibrotide |
DB00421 | DB00959 | 443 | 1,486 | [
"DDInter1707",
"DDInter1191"
] | Spironolactone | Methylprednisolone | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.[A11837, A178246] It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243, L6187] | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Moderate | 1 | [
[
[
443,
24,
1486
]
],
[
[
443,
1,
11347
],
[
11347,
40,
1486
]
],
[
[
443,
1,
1581
],
[
1581,
1,
1486
]
],
[
[
443,
24,
175
],
[
175,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortamate"
],
[
"Hydrocortamate",
... | Spironolactone (Compound) resembles Hydrocortamate (Compound) and Hydrocortamate (Compound) resembles Methylprednisolone (Compound)
Spironolactone (Compound) resembles Testolactone (Compound) and Testolactone (Compound) resembles Methylprednisolone (Compound)
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Spironolactone (Compound) binds NR3C1 (Gene) and NR3C1 (Gene) is bound by Methylprednisolone (Compound)
Spironolactone (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Methylprednisolone (Compound)
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Spironolactone (Compound) resembles Fluoxymesterone (Compound) and Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Spironolactone may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone |
DB01059 | DB01234 | 956 | 1,220 | [
"DDInter1313",
"DDInter513"
] | Norfloxacin | Dexamethasone | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Major | 2 | [
[
[
956,
25,
1220
]
],
[
[
956,
64,
870
],
[
870,
1,
1220
]
],
[
[
956,
64,
175
],
[
175,
40,
1220
]
],
[
[
956,
6,
21998
],
[
21998,
... | [
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone... | Norfloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Norfloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Norfloxacin (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Dexamethasone (Compound)
Norfloxacin (Compound) binds SLC22A5 (Gene) and SLC22A5 (Gene) is upregulated by Dexamethasone (Compound)
Norfloxacin (Compound) downregulates PPP2R5E (Gene) and PPP2R5E (Gene) is downregulated by Dexamethasone (Compound)
Norfloxacin (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Dexamethasone (Compound)
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sodium bicarbonate and Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Dexamethasone |
DB00390 | DB08901 | 1,252 | 1,468 | [
"DDInter554",
"DDInter1492"
] | Digoxin | Ponatinib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digitalis_ plant, studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1252,
24,
1468
]
],
[
[
1252,
24,
478
],
[
478,
24,
1468
]
],
[
[
1252,
6,
10083
],
[
10083,
45,
1468
]
],
[
[
1252,
7,
5057
],
[
5057... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nil... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Digoxin (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Ponatinib (Compound)
Digoxin (Compound) upregulates IL1B (Gene) and IL1B (Gene) is upregulated by Ponatinib (Compound)
Digoxin (Compound) downregulates AARS (Gene) and AARS (Gene) is upregulated by Ponatinib (Compound)
Digoxin (Compound) upregulates ATP6V0B (Gene) and ATP6V0B (Gene) is downregulated by Ponatinib (Compound)
Digoxin (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Ponatinib (Compound)
Digoxin (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Ponatinib (Compound)
Digoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib |
DB12010 | DB15328 | 214 | 829 | [
"DDInter785",
"DDInter1896"
] | Fostamatinib | Ubrogepant | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018] | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant] remain in clinical development.[A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative to its predecessors. Several parenteral monoclonal antibodies acting against the CGRP pathway (e.g. [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years. Ubrogepant was approved by Health Canada on November 10, 2022. Compared to the current standard of therapy for migraine treatment, namely triptans such as [sumatriptan] and [almotriptan], CGRP antagonists present several advantages. They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular disease. The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment of this debilitating condition. | Moderate | 1 | [
[
[
214,
24,
829
]
],
[
[
214,
24,
1476
],
[
1476,
24,
829
]
],
[
[
214,
63,
1468
],
[
1468,
24,
829
]
],
[
[
214,
64,
1510
],
[
1510,
... | [
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Fostamatinib may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Fostamatinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Ubrogepant
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant |
DB01206 | DB11601 | 37 | 1,270 | [
"DDInter1086",
"DDInter1889"
] | Lomustine | Tuberculin purified protein derivative | An alkylating agent of value against both hematologic malignancies and solid tumors. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
37,
24,
1270
]
],
[
[
37,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
37,
63,
869
],
[
869,
24,
1270
]
],
[
[
37,
64,
1064
],
[
1064,
... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine (Compound) resembles Carmustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.